MX2015009399A - Analogos de insulina truncados en n-terminal. - Google Patents

Analogos de insulina truncados en n-terminal.

Info

Publication number
MX2015009399A
MX2015009399A MX2015009399A MX2015009399A MX2015009399A MX 2015009399 A MX2015009399 A MX 2015009399A MX 2015009399 A MX2015009399 A MX 2015009399A MX 2015009399 A MX2015009399 A MX 2015009399A MX 2015009399 A MX2015009399 A MX 2015009399A
Authority
MX
Mexico
Prior art keywords
analogue
insulin
insulin analogue
insulin analogues
terminal truncated
Prior art date
Application number
MX2015009399A
Other languages
English (en)
Inventor
Michael Weiss
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of MX2015009399A publication Critical patent/MX2015009399A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un análogo de insulina contiene un polipéptido de cadena B reducida que carece de los residuos B1-B3 y opcionalmente contiene una sustitución adicional en el segmento B23-B30 C-terminal de la cadena B. El análogo de insulina que carece de los residuos B1-B3 puede contener sustituciones en B28 y/o B29 que confieren acción rápida y opcionalmente una sustitución no estándar en B24. El análogo puede ser un análogo de una insulina de mamífero, tal como insulina humana. También se proporciona un ácido nucleico que codifica tal análogo de insulina. Un método para tratar a un paciente comprende administrar una cantidad fisiológicamente efectiva del análogo de insulina o una sal fisiológicamente aceptable del mismo a un paciente. Se proporciona un método de semi-síntesis que usa un octapéptido no protegido por medio de la modificación de un sitio tríptico endógeno mediante sustituciones de aminoácido no estándares.
MX2015009399A 2013-01-22 2014-01-22 Analogos de insulina truncados en n-terminal. MX2015009399A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361755020P 2013-01-22 2013-01-22
PCT/US2014/012615 WO2014116753A1 (en) 2013-01-22 2014-01-22 N-terminal truncated insulin analogues

Publications (1)

Publication Number Publication Date
MX2015009399A true MX2015009399A (es) 2016-04-13

Family

ID=51228007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009399A MX2015009399A (es) 2013-01-22 2014-01-22 Analogos de insulina truncados en n-terminal.

Country Status (9)

Country Link
US (1) US9725493B2 (es)
EP (1) EP2948166B1 (es)
JP (1) JP2016506927A (es)
KR (1) KR20150110677A (es)
CN (1) CN105142660A (es)
BR (1) BR112015017492A2 (es)
CA (1) CA2937532A1 (es)
MX (1) MX2015009399A (es)
WO (1) WO2014116753A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094343A4 (en) * 2014-01-13 2017-10-18 Thermalin Diabetes, LLC Rapid action insulin formulations and pharmaceutical delivery systems
WO2016105545A2 (en) * 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
WO2017210242A1 (en) * 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Insulin-nuclear hormone conjugates
JP7286160B2 (ja) * 2016-11-21 2023-06-05 ケース ウェスタン リザーブ ユニバーシティ 安定性が増強された速効性インスリン類似体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
SE521356C2 (sv) * 1999-04-27 2003-10-28 Getinge Sterilization Aktiebol Fördelningsmedel för luftflöde
EP1196445A1 (en) * 1999-06-29 2002-04-17 Eli Lilly And Company Insulin crystals for pulmonary administration
KR20110061552A (ko) * 2008-07-31 2011-06-09 케이스 웨스턴 리저브 유니버시티 할로겐 안정화된 인슐린
NZ594248A (en) * 2009-01-28 2015-03-27 Smartcells Inc Conjugate based systems for controlled drug delivery
WO2013010048A2 (en) * 2011-07-13 2013-01-17 Case Western Reserve University Non-standard insulin analogues

Also Published As

Publication number Publication date
CN105142660A (zh) 2015-12-09
EP2948166B1 (en) 2020-12-09
WO2014116753A1 (en) 2014-07-31
EP2948166A1 (en) 2015-12-02
EP2948166A4 (en) 2016-10-12
US20150353621A1 (en) 2015-12-10
JP2016506927A (ja) 2016-03-07
BR112015017492A2 (pt) 2017-07-11
CA2937532A1 (en) 2014-07-31
US9725493B2 (en) 2017-08-08
KR20150110677A (ko) 2015-10-02

Similar Documents

Publication Publication Date Title
MY189079A (en) Insulin analogues with chlorinated amino acids
WO2010014946A3 (en) Halogen-stabilized insulin
NZ600709A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
JOP20150245B1 (ar) صياغات ذات مفعول طويل من الأنسولين
EA201291234A1 (ru) Аналоги глюкагона
AR105816A2 (es) Derivados de exendina-4 funcionalizada
TN2015000053A1 (en) Fusion proteins for treating a metabolic syndrome
MX2010011329A (es) Analogos de insulina especificos de isoforma.
AR096162A1 (es) Péptidos terapéuticos
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
WO2009129250A3 (en) Meal-time insulin analogues of enhanced stability
MX2015009399A (es) Analogos de insulina truncados en n-terminal.
EA201591529A1 (ru) Лечение детского дефицита гормона роста человеческими аналогами гормона роста
EA201590882A1 (ru) Одноцепочечные аналоги инсулина длительного действия
PH12015501931A1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2016105545A3 (en) Insulin analogues with enhanced stabilized and reduced mitogenicity
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
WO2013010048A3 (en) Non-standard insulin analogues
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
MY177371A (en) Peptides
MY200047A (en) Rapid-acting insulin analogues of enhanced stability
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
RU2017126212A (ru) Композиция
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії